Skip to main content

Clinical Evidence

Lilly's Zepbound 15 mg Outpaces Wegovy HD by 4.5% in New Weight-Loss Analysis

Lilly's Zepbound 15 mg Outpaces Wegovy HD by 4.5% in New Weight-Loss Analysis

Indianapolis – September 29, 2026 -- Eli Lilly and Company said a new indirect treatment comparison shows Zepbound (tirzepatide) 15 mg produced 4.5% greater body-weight loss than Novo Nordisk's Wegovy HD (semaglutide 7.2 mg) in adults with obesity, intensifying the competitive battle in the obesity-drug market. The 10 mg dose of Zepbound delivered 3.2% greater weight reduction than Wegovy HD, according to data presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan.

CSA Medical's RejuvenAir Cuts Severe COPD Exacerbations 38.4% in Pivotal Trial

CSA Medical's RejuvenAir Cuts Severe COPD Exacerbations 38.4% in Pivotal Trial

Boston – September 23, 2026 -- CSA Medical, Inc. announced publication in the American Journal of Respiratory and Critical Care Medicine of pivotal SPRAY-CB trial results showing its RejuvenAir System reduced severe COPD exacerbation rates by 38.4% versus a sham control.

Trial enrolled 210 patients across the US and UK despite optimal medical therapy

The randomized, blinded, sham-controlled SPRAY-CB trial (NCT03893370) tested Metered CryoSpray (MCS) therapy in patients with moderate-to-severe COPD and symptomatic chronic bronchitis who remained highly symptomatic despite receiving standard-of-care medication.